Update in hormone therapy use in menopause
- PMID: 21296989
- DOI: 10.1210/jc.2010-0536
Update in hormone therapy use in menopause
Abstract
The original report from the Women's Health Initiative (WHI) changed our understanding of the benefits and risks of hormone therapy. Since that time, reanalysis of the WHI and additional data from other studies have further refined these concepts. Here we provide an update on recent advances in the field. Menopausal hormone therapy continues to have a clinical role in the management of vasomotor symptoms. However, our understanding of the role of hormones in cardiovascular disease and breast cancer continues to evolve. Further analyses of the effect of age and proximity to menopause at the time of initiation of therapy, duration of treatment, dose, route of administration, and the persistence of risks and benefits after stopping hormone therapy are described. In addition, recent data have emerged suggesting that there may be a link between hormone therapy and cancers of the lung and ovary. Finally, we discuss new advances in hormone therapy that will likely lead to a more favorable benefit-to-risk ratio, enabling safer effective menopausal symptom relief.
Similar articles
-
Recent epidemiological evidence relevant to the clinical management of the menopause.Climacteric. 2007 Oct;10 Suppl 2:2-15. doi: 10.1080/13697130701606754. Climacteric. 2007. PMID: 17882666 Review.
-
Where are we with postmenopausal hormone therapy in 2005?Gynecol Endocrinol. 2005 Nov;21(5):248-56. doi: 10.1080/09513590500279733. Gynecol Endocrinol. 2005. PMID: 16373243 Review.
-
The rise and fall of menopausal hormone therapy.Annu Rev Public Health. 2005;26:115-40. doi: 10.1146/annurev.publhealth.26.021304.144637. Annu Rev Public Health. 2005. PMID: 15760283 Review.
-
Hormone replacement therapy and cancer.Gynecol Endocrinol. 2001 Dec;15(6):453-65. Gynecol Endocrinol. 2001. PMID: 11826770 Review.
-
Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.Am J Epidemiol. 2009 Jul 1;170(1):24-8. doi: 10.1093/aje/kwp113. Epub 2009 May 25. Am J Epidemiol. 2009. PMID: 19468078
Cited by
-
No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50.BMC Neurol. 2013 Jul 3;13:73. doi: 10.1186/1471-2377-13-73. BMC Neurol. 2013. PMID: 23822612 Free PMC article.
-
Complementary and alternative medicine in the treatment of menopausal symptoms.Chin J Integr Med. 2011 Dec;17(12):883-8. doi: 10.1007/s11655-011-0932-7. Epub 2011 Dec 3. Chin J Integr Med. 2011. PMID: 22139538 Review.
-
Impact of Phytoestrogens on Serum Lipids in Postmenopausal Women.Geburtshilfe Frauenheilkd. 2012 Jun;72(6):527-531. doi: 10.1055/s-0031-1298624. Geburtshilfe Frauenheilkd. 2012. PMID: 25284841 Free PMC article.
-
Genistein Supplementation and Cardiac Function in Postmenopausal Women with Metabolic Syndrome: Results from a Pilot Strain-Echo Study.Nutrients. 2017 Jun 7;9(6):584. doi: 10.3390/nu9060584. Nutrients. 2017. PMID: 28590452 Free PMC article. Clinical Trial.
-
Dietary factors in the etiology of Parkinson's disease.Biomed Res Int. 2015;2015:672838. doi: 10.1155/2015/672838. Epub 2015 Jan 20. Biomed Res Int. 2015. PMID: 25688361 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources